Fungal dysbiosis regulation of post-influenza bacterial pneumonia
Fungal dysbiosis regulation of post-influenza bacterial pneumonia
批准号:
10654630
负责人:
PETER CHEN
金额:
$59.71万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-16 至 2025-06-30
关键词:
AcuteAdoptive TransferAffectAllergicAlveolar MacrophagesAntibiotic TherapyAntibioticsBacteriaBacterial PneumoniaCessation of lifeChronicColitisCommunitiesDataDevelopmentDiseaseEosinophiliaEpidemicEpithelial CellsEpitheliumFecesFunctional disorderGastrointestinal tract structureGnotobioticGoalsGrantHelminthsHomeostasisHumanImmuneImmune systemImmunityImmunocompetentImpairmentIn VitroInfectionInflammatoryInflammatory ResponseInfluenzaInterferon Type IILungMacrophageMediatingMediatorMedicalMedicineMethodsModelingMorbidity - disease rateMucous MembraneMusNutritionalOrganismPathologyPatientsPhenotypePneumoniaPredispositionPreventive measurePublishingPulmonary InflammationPulmonary PathologyRecoveryRegulationRiskRoleSaccharomyces cerevisiaeSamplingSerumSignal TransductionStaphylococcus aureus infectionTestingTissuesUric AcidVeinsViralVirus DiseasesWorkallergic responsebacterial resistancebacteriomeclinical practicecommensal bacteriacytokinedysbiosiseosinophilfightingfungusgut microbiotahigh riskimmune functionimmunoregulationin vitro Modelin vivoinfluenza infectioninfluenza pneumoniainfluenzavirusinnate immune functionlung injurymethicillin resistant Staphylococcus aureusmicrobiome alterationmortalitymouse modelmycobiomenovel therapeuticspathogenpathogenic bacteriapressureprogramsprophylacticrecruitregenerative cellsuperinfectiontranslational study
中文摘要
项目总结
英文摘要
Project summary
The discovery of antibiotics in the early 20th century opened up a new era of medical treatment. Indeed, many
present-day infections that are easily treated could have had deadly consequences in the absence of antibiotics.
The overuse of these medicines has been a concern in the recent years due to the selection pressures that have
allowed resistant bacterial species to emerge. However, another untoward consequence of antibiotics is that
treatment can alter the commensal organisms of the body, which we now understand has important homeostatic
functions. Indeed, many bacterial, fungal, and viral organisms that live within tissues of the body can condition
the immunologic system, and an altered microbiome, such as with antibiotic use, can contribute to the
development of many acute and chronic pathologies. As such, our studies demonstrate that giving prophylactic
antibiotics during influenza infection (a common clinical practice) increases the risk for development of a
secondary bacterial pneumonia, which is major reason for the morbidity and mortality from the initial viral illness.
Although antibiotics have direct effects on decreasing the abundance and diversity of the bacterial microbiome,
the newly available niche with reduced nutritional competition provides an opportunity for expansion of fungal
communities. Our data demonstrates that fungal dysbiosis is a driver of worsened secondary bacteria pneumonia
after influenza infection. Moreover, we find that antibiotic-induced fungal dysbiosis increases lung inflammation
including augmented interferon-γ levels, a cytokine that can clear detrimental effects that contribute to post-
influenza bacterial pneumonia. Finally, we find that eosinophils partially modulate the augmented lung injury,
and increased gut S. cerevisiae correlates with the phenotype induced by fungal dysbiosis. Altogether, these
findings support our central hypothesis that antibiotic treatment during influenza infection causes fungal dysbiosis
that has lung immunomodulatory effects, which in turn increases the host susceptibility to bacterial
superinfection. We will test this hypothesis in the following aims:
Aim 1. Determine if fungal dysbiosis alters innate immune functions in post-influenza pneumonia.
Aim 2. Evaluate how fungal dysbiosis causes lung eosinophilia to augment lung inflammation.
Aim 3. Investigate the role of S. cerevisiae in mediating lung injury from post-influenza MRSA pneumonia.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Comparison of clinical characteristics and outcomes of critically ill adults with SARS-CoV-2 infection during Delta and Omicron variant predominance periods: a single-hospital retrospective cohort study.
Delta 和 Omicron 变异优势期 SARS-CoV-2 感染危重成人的临床特征和结果比较:单医院回顾性队列研究。
DOI:
10.1136/bmjresp-2022-001274
发表时间:
2023-02
期刊:
BMJ open respiratory research
影响因子:
4.1
作者:
[]
通讯作者:
DOI:
10.7554/elife.85415
发表时间:
2023-06-14
期刊:
eLife
影响因子:
7.7
作者:
[Liang J, Huang G, Liu X, Liu N, Taghavifar F, Dai K, Yao C, Deng N, Wang Y, Chen P, Hogaboam C, Stripp BR, Parks WC, Noble PW, Jiang D]
通讯作者:
Jiang D
DOI:
10.3389/fimmu.2021.790469
发表时间:
2021
期刊:
Frontiers in immunology
影响因子:
7.3
作者:
[Zhang L, Poorbaugh J, Dougan M, Chen P, Gottlieb RL, Huhn G, Beasley S, Daniels M, Ngoc Vy Trinh T, Crisp M, Freitas JJ, Vaillancourt P, Patel DR, Nirula A, Kallewaard NL, Higgs RE, Benschop RJ]
通讯作者:
Benschop RJ
DOI:
10.1002/cpt.2405
发表时间:
2021-12
期刊:
Clinical pharmacology and therapeutics
影响因子:
6.7
作者:
[Chen P, Datta G, Grace Li Y, Chien J, Price K, Chigutsa E, Brown-Augsburger P, Poorbaugh J, Fill J, Benschop RJ, Rouphael N, Kay A, Mulligan MJ, Saxena A, Fischer WA, Dougan M, Klekotka P, Nirula A, Benson C]
通讯作者:
Benson C
DOI:
10.1038/s41598-023-35840-y
发表时间:
2023-05-27
期刊:
SCIENTIFIC REPORTS
影响因子:
4.6
作者:
[Cerro-Chiang, Giuliana, Ayres, Matthew, Rivas, Alejandro, Romero, Tahmineh, Parker, Sarah J., Mastali, Mitra, Elashoff, David, Chen, Peter, Van Eyk, Jennifer E., Wolters, Paul J., Boin, Francesco, Zaman, Tanzira]
通讯作者:
Zaman, Tanzira
共 6 条
Syndecan-1 suppression of lung inflammation
-
批准号:10463119
-
项目类别:
-
资助金额:$60.02万
-
财政年份:2022
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 suppression of lung inflammation
-
批准号:10613558
-
项目类别:
-
资助金额:$60.02万
-
财政年份:2022
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 suppression of lung inflammation
-
批准号:10792072
-
项目类别:
-
资助金额:$12.71万
-
财政年份:2022
-
负责人:PETER CHEN
-
依托单位:
Fungal dysbiosis regulation of post-influenza bacterial pneumonia
-
批准号:10097806
-
项目类别:
-
资助金额:$59.71万
-
财政年份:2021
-
负责人:PETER CHEN
-
依托单位:
Fungal dysbiosis regulation of post-influenza bacterial pneumonia
-
批准号:10452478
-
项目类别:
-
资助金额:$59.71万
-
财政年份:2021
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 Regulations of Influenza Infection
-
批准号:9198040
-
项目类别:
-
资助金额:$42.5万
-
财政年份:2014
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 Regulations of Influenza Infection
-
批准号:8812061
-
项目类别:
-
资助金额:$41.07万
-
财政年份:2014
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 in Lung Repair
-
批准号:8616778
-
项目类别:
-
资助金额:$4.43万
-
财政年份:2011
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 in Lung Repair
-
批准号:8855470
-
项目类别:
-
资助金额:$38.2万
-
财政年份:2011
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 in Lung Repair
-
批准号:8461300
-
项目类别:
-
资助金额:$41.35万
-
财政年份:2011
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 in Lung Repair
-
批准号:8105273
-
项目类别:
-
资助金额:$42.75万
-
财政年份:2011
-
负责人:PETER CHEN
-
依托单位:
Syndecan-1 in Lung Repair
-
批准号:8254390
-
项目类别:
-
资助金额:$43.19万
-
财政年份:2011
-
负责人:PETER CHEN
-
依托单位:
Epigenetic Gene Regulation by the Ocular Environment
-
批准号:7579838
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2007
-
负责人:PETER CHEN
-
依托单位:
Epigenetic Gene Regulation by the Ocular Environment
-
批准号:7209643
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2007
-
负责人:PETER CHEN
-
依托单位:
The Role of TIMP-1 in Airway Epithelial Repair
-
批准号:7790603
-
项目类别:
-
资助金额:$12.91万
-
财政年份:2007
-
负责人:PETER CHEN
-
依托单位:
The Role of TIMP-1 in Airway Epithelial Repair
-
批准号:7190637
-
项目类别:
-
资助金额:$2.67万
-
财政年份:2007
-
负责人:PETER CHEN
-
依托单位:
The Role of TIMP-1 in Airway Epithelial Repair
-
批准号:7382584
-
项目类别:
-
资助金额:$12.91万
-
财政年份:2007
-
负责人:PETER CHEN
-
依托单位:
The Role of TIMP-1 in Airway Epithelial Repair
-
批准号:8040027
-
项目类别:
-
资助金额:$12.91万
-
财政年份:2007
-
负责人:PETER CHEN
-
依托单位:
Epigenetic Gene Regulation by the Ocular Environment
-
批准号:8018123
-
项目类别:
-
资助金额:$29.84万
-
财政年份:2007
-
负责人:PETER CHEN
-
依托单位:
Epigenetic Gene Regulation by the Ocular Environment
-
批准号:7927836
-
项目类别:
-
资助金额:$20.34万
-
财政年份:2007
-
负责人:PETER CHEN
-
依托单位:
海外基金